Industry: Acquisition of others Location: Japan Transaction price: US$1 million Transaction method: Equity financing
❖ Basic company information
business content
Japanese companies and medical corporations that provide cancer immune cell (NK cell) therapy
feature
① Natural killer cells (NK cells) are collected from the patient's peripheral blood, cultured in large quantities, and then returned to the patient for use in the patient's own cancer. At the same time, it provides frozen NK cell service for healthy people, which plays a preventive role in case of emergency.
② The company is located in Minato-ku, Tokyo, and has obtained a number of patents.
③ In addition to the turnover of the clinics under the medical corporation, the sales of the enterprise also include the cryopreservation fee to external customers and the sales of cell culture media.
④ As a clinic specializing in NK cells, the medical corporation has provided the above-mentioned NK cells to more than 1,400 patients. Accept domestic patients and overseas patients introduced by overseas tourism and medical cooperation companies.
⑤ Cooperate with Chinese medical companies to provide Chinese patients with highly active NK cells through cell culture methods.
Established: 2004
Number of employees: 25 (including R&D, technical personnel, medical staff)
❖ Financial Information
Non-disclosed information, please contact our company for details.
❖ Other
Shareholder composition:
40.2% of representatives of corporate legal persons,
2 directors 16.1%,
Director personal asset management company 6.2%,
Outside shareholders 25.0%,
Treasury shares 12.5%.
There are other potential shares (stock options)
Transfer plan:
Whole or partial share transfer (shares of external shareholders can be negotiated).
Remaining of directors after transfer:
Six months to one year after handover, the former directors plan to leave (the healthcare-related staff will not leave).